JPRN-UMIN000016469已完成2 期
Phase II study of intraperitoneal docetaxel combined with capecitabine plus cisplatin for advanced gastric cancer with peritoneal metastasis - Phase II study of XP+IP DOC
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Metastasis to distant organ sites (such as the liver, lungs or bone), other active concomitant malignancies, or other severe medical conditions
研究者
相似试验
已完成
1 期
Phase I study of intraperitoneal docetaxel combined with capecitabine plus cisplatin for advanced gastric cancer with peritoneal metastasisgastric cancer with peritoneal metastasisJPRN-UMIN000012971The University of Tokyo12
已完成
不适用
A phase I trial of intraperitoneal docetaxel and cisplatin with S-1 for treatment of gastric cancer with peritoneal disseminatiogastric cancer with periotoneal metastasisJPRN-UMIN000021376Department of Gastroenterologic Surgery, Kanazawa Universiy30
已完成
1 期
Phase I study of intraperitoneal docetaxel and irinotecan for advanced gastric cancer with peritoneal metastasisgastric cancer with peritoneal metastasisJPRN-UMIN000017084The University of Tokyo12
进行中（未招募）
不适用
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - DOCOX GASTRIC (Docetaxel-Oxaliplatin in Gastric Cancer)Metastatic or local recurrent gastric cancer previously untreated with chemotherapy for advance disease.MedDRA version: 8.1Classification code 10017758EUCTR2005-005464-92-HUSanofi-aventis groupe270
进行中（未招募）
不适用
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - GATE (GAstric cancer study with Taxotere-Eloxatin-based regimens)Metastatic or local recurrent gastric cancer previously untreated with chemotherapy for advance disease.MedDRA version: 8.1Classification code 10017758EUCTR2005-005464-92-BESanofi-aventis groupe270